Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck Sharp & Dohme LLC
With
Eisai Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Has a diagnosis of HCC confirmed by radiology, histology, or cytology
Has HCC localized to the liver and not amenable to curative treatment
Participants with Hepatitis B virus (HBV) are eligible
Has adequately controlled blood pressure with or without antihypertensive medications
Has adequate organ function
You may not be if
Is currently a candidate for liver transplantation
Has had gastric bleeding within the last 6 months
Has ascites that is not controlled with medication
Has significant cardiovascular impairment within 12 months of the first dose of study intervention such as congestive heart failure
Has a serious nonhealing wound, ulcer, or bone fracture
Has received locoregional therapy to existing liver lesions
Clareo Health | Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
